These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 6190686

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Closer correlation between serum triiodothyronine and basal metabolic rate during antithyroid drug treatment in patients with Graves' disease.
    Hamada N, Miura T, Ban Y, Momotani N, Nishikawa Y, Ohno M, Morii H, Kitabatake S, Ito K.
    Endocrinol Jpn; 1978 Apr; 25(2):117-22. PubMed ID: 78844
    [Abstract] [Full Text] [Related]

  • 6. Serum free triiodothyronine to free thyroxine ratio enables early prediction of the outcome of antithyroid drug therapy in patients with Graves' hyperthyroidism.
    Tajiri J, Noguchi S, Morita M, Tamaru M, Murakami N, Kato R.
    Endocrinol Jpn; 1991 Dec; 38(6):683-7. PubMed ID: 1726635
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism.
    Tsai WC, Pei D, Wang TF, Wu DA, Li JC, Wei CL, Lee CH, Chen SP, Kuo SW.
    Clin Endocrinol (Oxf); 2005 May; 62(5):521-4. PubMed ID: 15853819
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Antithyroid drug treatment prior to radioiodine therapy for Graves' disease: yes or no?
    Bogazzi F, Martino E, Bartalena L.
    J Endocrinol Invest; 2003 Feb; 26(2):174-6. PubMed ID: 12739747
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Short-term antithyroid drug therapy for the thyrotoxicosis of Graves's disease.
    Greer MA, Kammer H, Bouma DJ.
    N Engl J Med; 1977 Jul 28; 297(4):173-6. PubMed ID: 69269
    [Abstract] [Full Text] [Related]

  • 14. Thyroid over-expression of type 1 and type 2 deiodinase may account for the syndrome of low thyroxine and increasing triiodothyronine during propylthiouracil treatment.
    Weetman AP, Shepherdley CA, Mansell P, Ubhi CS, Visser TJ.
    Eur J Endocrinol; 2003 Nov 28; 149(5):443-7. PubMed ID: 14585092
    [Abstract] [Full Text] [Related]

  • 15. [Treatment of T3-predominant Graves' disease].
    Lin LX.
    Zhonghua Yi Xue Za Zhi; 1988 Feb 28; 68(2):79-81. PubMed ID: 2457417
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Long term antithyroid drug therapy for intractable cases of Graves' disease.
    Shizume K.
    Endocrinol Jpn; 1978 Aug 28; 25(4):377-9. PubMed ID: 81772
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.